Risdiplam (EVRYSDI®) is a centrally and peripherally distributed, oral survival of motor neuron 2 (SMN2) pre-mRNA splicing modifier approved for the treatment of spinal muscular atrophy (SMA) in more than 90 countries worldwide. GYM329 is an investigational, recycling and antigen-sweeping mon...